AEterna Zentaris (TSX:AEZS) 6-1 Month Momentum %

: 23.38% (As of Today)

View and export this data going back to 1995. Start your Free Trial

6-1 Month Momentum % is the total return of the stock from 6-month ago to 1-month ago. As of today (2024-04-19), AEterna Zentaris's 6-1 Month Momentum % is 23.38%.

The industry rank for AEterna Zentaris's 6-1 Month Momentum % or its related term are showing as below:

TSX:AEZS's 6-1 Month Momentum % is ranked better than
70.05% of 1519 companies
in the Biotechnology industry
Industry Median: -1.21 vs TSX:AEZS: 23.38

Competitive Comparison

For the Biotechnology subindustry, AEterna Zentaris's 6-1 Month Momentum %, along with its competitors' market caps and 6-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AEterna Zentaris 6-1 Month Momentum % Distribution

For the Biotechnology industry and Healthcare sector, AEterna Zentaris's 6-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where AEterna Zentaris's 6-1 Month Momentum % falls into.

AEterna Zentaris (TSX:AEZS) 6-1 Month Momentum % Calculation

6-1 Month Momentum % is calculated as following:

6-1 Month Momentum %

( Price 1-month ago

Price 6-month ago

- 1 )

100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AEterna Zentaris (TSX:AEZS) 6-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 6-1 Month Momentum % measures the total return to a stock over the past six months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

AEterna Zentaris 6-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of AEterna Zentaris's 6-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.

AEterna Zentaris (TSX:AEZS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AEterna Zentaris Inc (TSX:AEZS) » Definitions » 6-1 Month Momentum %

Comparable Companies

Traded in Other Exchanges

AEZS:USA ET8:Germany

Address

222 Bay Street, Suite 3000, PO Box 53, c/o Norton Rose Fulbright Canada, LLP, Toronto, ON, CAN, M5K 1E7

Website

https://www.zentaris.com

AEterna Zentaris Inc is a biopharmaceutical company commercializing & developing therapeutics & diagnostic tests. The company's product, Macrilen (macimorelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (GHD). Macrilen is marketed in the U.S. through a license agreement with Novo Nordisk & the company receives royalties on sales. Aeterna owns all rights to macimorelin outside of the U.S. & Canada. It is leveraging the clinical success & safety profile of macimorelin to develop it for the diagnosis of child-onset GHD. The company's geographical segments include Switzerland, Ireland, Denmark, and others, of which nearly all of its revenue comes from Switzerland.